U.S. Bioreactors Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

U.S. Bioreactors Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032


The U.S. bioreactors market was valued at approximately USD 3.8 billion in 2023. Projections indicate a robust growth trajectory, with an estimated CAGR of 11% from 2024 to 2032. The surge in demand for biopharmaceuticals in the U.S., coupled with technological advancements in bioreactors, is propelling this market growth. Innovations such as single-use bioreactors are drawing attention for their cost-effectiveness and enhanced process efficiency. These attributes resonate with biopharmaceutical manufacturers aiming for streamlined production.

In October 2021, Waters Corporation and Sartorius AG formed a strategic alliance to provide bioprocess experts with swift access to premium mass spectrometry (MS) data, enhancing the speed and precision of biopharmaceutical process development. This collaboration integrated Waters Corporation's BioAccord LC-MS System with Sartorius AG's Ambr multi-parallel bioreactor systems, offering in-depth mass spectral insights on drug substances, associated analytes, and cell culture media, streamlining processes from clone selection to bioprocess optimization.

The market is poised for significant growth, driven by the increasing adoption of single-use bioreactors. These bioreactors minimize the risk of cross-contamination, demand lower capital investment, and offer enhanced flexibility, making them especially appealing to small-scale and multiproduct manufacturing facilities.

The U.S. bioreactors industry is categorized based on product type, cell, molecule, material, size, usage, end-use, and region.

In 2023, the reusable segment led with a revenue of USD 2.8 billion. Reusable bioreactors, favored for their cost-effectiveness in large-scale production, can be sterilized and reused, unlike their single-use counterparts. This feature offers significant long-term savings, especially in biopharmaceuticals requiring large batches. Their robustness allows them to handle diverse operational conditions, making them ideal for complex, high-yield processes and specific material requirements.

Market segmentation by molecule type includes monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and others. The vaccines segment topped the revenue chart with USD 1.9 billion in 2023. Bioreactors play a crucial role in cultivating cells for vaccine production, ensuring optimal conditions for maximum yield and quality. Their adaptability allows for various production processes, from live attenuated to subunit vaccines.

Market segmentation by end-use includes R&D organizations, biopharma manufacturers, and contract manufacturing organizations. Biopharma manufacturers segment led with a revenue of USD 1.7 billion in 2023 and is poised for significant growth through 2032. The demand for biologics, which require advanced manufacturing, ushers this segment. With a focus on personalized medicine and targeted therapies, biopharma manufacturers are investing in adaptable bioreactor systems for specialized production runs.

The U.S. bioreactor sector is competitive, with major and medium-sized companies vying for dominance. Key strategies include introducing innovations like automation, integrated sensors, and hybrid bioreactors. Major vendors, through substantial R&D investments, often lead these advancements. Furthermore, strategic alliances, acquisitions, and mergers bolster market positions amidst changing regulations.


Chapter 1 Methodology and Scope
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing pharmaceutical and biotechnology industry
3.2.1.2 Technological advancements in bioreactors
3.2.1.3 Growing focus on orphan drug development
3.2.1.4 Rising demand for personalized medicines
3.2.2 Industry pitfalls and challenges
3.2.2.1 Low capacity of single-use bioreactors
3.2.2.2 Concerns regarding extractables and/or leachables
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2032 ($ Mn, Units)
5.1 Key trends
5.2 Single-use
5.2.1 Size
5.2.1.1 Less than 500 L
5.2.1.2 501-5,000 L
5.2.1.3 More than 5,000 L
5.3 Reusable
5.3.1 Size
5.3.1.1 Less than 500 L
5.3.1.2 501-5,000 L
5.3.1.3 More than 5,000 L
5.3.2 Material
5.3.2.1 Stainless steel
5.3.2.2 Glass
Chapter 6 Market Estimates and Forecast, By Cell, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Mammalian cells
6.3 Bacterial cells
6.4 Yeast cells
6.5 Other cells
Chapter 7 Market Estimates and Forecast, By Molecule, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Monoclonal antibodies
7.3 Vaccines
7.4 Recombinant proteins
7.5 Stem cells
7.6 Gene therapy
7.7 Other molecules
Chapter 8 Market Estimates and Forecast, By Usage, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Developmental, pre-clinical and clinical
8.3 Commercial production
Chapter 9 Market Estimates and Forecast, By Material, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Stainless steel
9.2.1 Size
9.2.1.1 Less than 500 L
9.2.1.2 501-5,000 L
9.2.1.3 More than 5,000 L
9.3 Glass
9.4 Single-use
Chapter 10 Market Estimates and Forecast, By Size, 2021 – 2032 ($ Mn)
10.1 Less than 500 L
10.1.1 Single-use
10.1.2 Reusable
10.1.2.1 Stainless Steel
10.1.2.2 Glass
10.2 501-5,000 L
10.2.1 Single-use
10.2.2 Reusable
10.3 More than 5,000 L
10.3.1 Stainless steel
10.3.2 Single-Use
Chapter 11 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 R&D organizations
11.3 Biopharma manufacturers
11.4 Contract manufacturing organizations (CMOs)
Chapter 12 Company Profiles
12.1 Altrad Group
12.2 BaiLun Biotechnology Co., Ltd
12.3 Danaher Corporation
12.4 Donaldson Company, Inc
12.5 Eppendorf Group
12.6 Esco Micro Pte. Ltd.
12.7 GEA Group Aktiengesellschaft
12.8 Getinge AB
12.9 Merck KGaA
12.10 PBS Biotech, Inc.
12.11 Sartorius AG
12.12 Thermo Fisher Scientific Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings